Examples of Neotope Biosciences in a sentence
Prothena's business consists of a substantial portion of Elan's former drug discovery business platform, including Neotope Biosciences Limited and its wholly owned subsidiaries Onclave Therapeutics Limited and Prothena Biosciences Inc (which for the period prior to separation and distribution are collectively referred to herein as the “Prothena Business”).
Prothena's business consists of a substantial portion of Elan's former drug discovery business platform, including Neotope Biosciences Limited and its wholly owned subsidiaries Onclave Therapeutics Limited and Prothena Biosciences Inc (which for the period prior to separation and distribution are referred to herein as the “Prothena Business”).
Prothena's business consists of a substantial portion of Elan's former drug discovery business platform, including Neotope Biosciences Limited and its wholly owned subsidiaries Onclave Therapeutics Limited and Prothena Biosciences Inc (which for the period prior to the separation and distribution are collectively referred to herein as the “Prothena Business”).
The Company’s subsidiaries are Prothena Biosciences Limited (formerly known as Neotope Biosciences Limited), Prothena Therapeutics Limited (formerly known as Onclave Therapeutics Limited), both of which are located in Ireland, and Prothena Biosciences Inc, which is located in the U.S. PROPERTIES Our corporate headquarters are located in Dublin, Ireland and our U.S. operations are located in South San Francisco, California.
Parent shall procure that, effective as of the Closing Date, Neotope Biosciences and Onclave shall cease to be members of a group within the meaning of section 15 of the VATCA in respect of which any Parent Group member is also a member (a “ VAT Group ”).
Neotope Master Process Development and Clinical Supply Agreement / Appendix 2B-2 confidential Appendix 2B-2: [***] Project Plan — [***] [***] Neotope Biosciences Limited (“Neotope”), Elan Pharma International Limited (“EPIL”) and Boehringer Ingelheim Pharma GmbH & Co. KG (“BI Pharma”) entered into a Master Process Development and Clinical Supply Agreement effective June 23, 2010 (the “Original MSA”).
If to Neotope: Neotope Biosciences Limited Monksland Athlone, County Westmeath Ireland Attention: Director Fax: [***] With a copy to: Neotope Biosciences, a division of Elan Pharmaceuticals, Inc.
Each “significant subsidiary” of the Company (as such term is defined in Rule 1-02 of Regulation S-X, which, for the avoidance of doubt, shall include Prothena Biosciences Limited (formerly Neotope Biosciences Limited), Othair Prothena Limited, Prothena Pharma Limited, Prothena Platform Technologies Limited, Prothena Biosciences Inc.
Form of Intellectual Property License and Conveyance Agreement among Neotope Biosciences Limited, Elan Pharma International Limited and Elan Pharmaceuticals, Inc.
If to Prothena: Neotope Biosciences Limited 00-00 Xxxxx Xxxx Xxxx Xxxxxx 0, Xxxxxxx Attention: Director Facsimile: +000 0 000 0000 and Prothena Biosciences Inc 000 Xxxxxxx Xxxxxxxxx Xxxxx Xxx Xxxxxxxxx, XX 00000, X.X.X. Attention: Secretary Facsimile: +0 000 000 0000 With a copy to: Xxxxxx & Xxxxxxx LLP 000 Xxxxx Xxxxx Menlo Park, CA 94025, U.S.A. Attention: Xxxx Xxxxxxxxx and Xxxxxx Xxxxx Facsimile: +0 000 000 0000 If to Roche: X.